I. Bouaziz, R. Atheymen, R. Sahnoun, K. Ksouda, H. Affes, S. Hammami, K. Zghal
{"title":"Intérêt des patch tests dans l’exploration des réactions d’hypersensibilité retardée aux antiépileptiques","authors":"I. Bouaziz, R. Atheymen, R. Sahnoun, K. Ksouda, H. Affes, S. Hammami, K. Zghal","doi":"10.1016/j.reval.2025.104568","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The aim of our study was to evaluate the utility of the patch-tests for the diagnosis of the delayed hypersensitivity reactions induced by antiepileptic drugs and to explore cross-reactivity between them.</div></div><div><h3>Patients and methods</h3><div>We included cases of delayed drug addiction to antiepileptics notified to the Sfax regional pharmacovigilance center during the period from January 2019 to June 2023. We used the French Bégaud method for the study of imputability. Patch testing was performed in all patients according to the recommendations of the European Network of Drug Allergy. The interpretation of the results was made according to the rules of the International Contact Dermatitis Research Group.</div></div><div><h3>Results</h3><div>We included 17 delayed drug reactions: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome (<em>n</em> <!-->=<!--> <!-->10), maculopapular rash (<em>n</em> <!-->=<!--> <!-->6), Stevens-Johnson syndrome (<em>n</em> <!-->=<!--> <!-->1). Patch tests were positive in 76.47% of cases: 66.66% for maculopapular rash with cross-reactivity between carbamazepine and phenobarbital (<em>n</em> <!-->=<!--> <!-->1) and 90% in DRESS syndrome with cross-reactivity between 2 or more antiepileptics (<em>n</em> <!-->=<!--> <!-->5). For the patient with Stevens-Johnson syndrome, the tests were interpreted as irritating.</div></div><div><h3>Conclusion</h3><div>Patch tests are safe and useful to confirm the imputability of antiepileptic drugs in the genesis of delayed drug hypersensibility reaction and to detect possible cross-reactivity.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"65 5","pages":"Article 104568"},"PeriodicalIF":0.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Francaise d Allergologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877032025003409","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
The aim of our study was to evaluate the utility of the patch-tests for the diagnosis of the delayed hypersensitivity reactions induced by antiepileptic drugs and to explore cross-reactivity between them.
Patients and methods
We included cases of delayed drug addiction to antiepileptics notified to the Sfax regional pharmacovigilance center during the period from January 2019 to June 2023. We used the French Bégaud method for the study of imputability. Patch testing was performed in all patients according to the recommendations of the European Network of Drug Allergy. The interpretation of the results was made according to the rules of the International Contact Dermatitis Research Group.
Results
We included 17 delayed drug reactions: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome (n = 10), maculopapular rash (n = 6), Stevens-Johnson syndrome (n = 1). Patch tests were positive in 76.47% of cases: 66.66% for maculopapular rash with cross-reactivity between carbamazepine and phenobarbital (n = 1) and 90% in DRESS syndrome with cross-reactivity between 2 or more antiepileptics (n = 5). For the patient with Stevens-Johnson syndrome, the tests were interpreted as irritating.
Conclusion
Patch tests are safe and useful to confirm the imputability of antiepileptic drugs in the genesis of delayed drug hypersensibility reaction and to detect possible cross-reactivity.
期刊介绍:
La Revue Française d''Allergologie : un véritable forum pour faire connaître des travaux originaux et permettre la diffusion de l''information auprès de toutes les spécialités concernées par les pathologies allergiques. La Revue Française d''Allergologie (8 numéros par an) est au carrefour de nombreuses spécialités - dermatologie, pédiatrie, ORL, pneumologie, ophtalmologie, médecine interne - qui, toutes, ont à traiter des maladies allergiques. Les symptômes des allergies fondés sur des mécanismes communs sont le plus souvent associés et se succèdent chez un même patient. En forte progression depuis 20 ans, les maladies allergiques sont dans l''attente de perfectionnements et d''avancées thérapeutiques qui permettront aux nombreux patients qui en sont atteints de mieux vivre avec leurs allergies. La Revue Française d''Allergologie se veut donc un véritable forum de discussions et d''échanges entre tous les spécialistes confrontés aux pathologies